In 2022, 3DS achieved:
a) Several novel candidate anticancer agents with high in vitro efficacy, eg picolylamine-functionalized benz[e]indole squaraine dyes for photodynamic therapy; novel cytotoxic steroids and cyanines dyes (https://doi.org/10.1016/j.ejmech.2021.114071, https://doi.org/10.3390/molecules27186126, https://doi.org/10.3390/molecules27185779);
b) In vitro stabilization of an important drug target in Parkinsion’s Disease (the membrane-bound Catechol-O-methyltransferase) and discovery of novel inhibitors of this enzyme
(https://doi.org/10.3390/ijms23137264, https://doi.org/10.3390/ph15010051);
c) The identification of potential biomarkers of female infertility by volatilomics
(https://doi.org/10.3390/biomedicines10112852) [Collaboration with NND group];
d) Novel efficient delivery strategy (intranasal nanosystem) for the antiepileptic perampanel. (https://doi.org/10.1016/j.ijpharm.2022.121853) and innovative homogenous nanoemulsion compositions with a low energy method of preparation, with high lipid content and great solubilization ability for lipophilic drugs. (International Application Number: PCT/IB2022/055385);
e) Evidence of reduction of potentially inappropriate medication in older patients by interventions in the community.
(https://doi.org/10.3389/fphar.2021.777655).